MEDX Oncology West


Session 8: Targeting EGFR, T790M, ALK, and ROS1 in NSCLC

Saturday, November 18     10:15am – 11:15am

Description

Oncology treatment teams are tasked with navigating through a steady increase in the number and complexity of molecular biomarkers that guide treatment decisions. FDA-approved companion tests have expanded testing options and provided uniformity of reporting, yet challenges in the clinical setting and the potential to negatively affect patient outcomes persist. As part of the continuum of care in oncology, there is an increasing demand for genomic testing and retesting for clinicians to provide interpretations that may alter the course of treatment.

Cross-disciplinary skills are encouraged among the interdisciplinary treatment teams to prevent misinterpretation and over-interpretation of tests that can be confusing. There is no shortage of targeted agents for the well-established molecular subtypes of non-small cell lung cancer (NSCLC); however, selecting the right agents for the right patients remains a challenge in the community setting.

Appropriate evidence-based care and demonstration of high-quality are consistent with clinical guidelines and will directly affect reimbursement incentives within the new payment models.

Session Outline

Faculty will discuss 2-3 patient stories to highlight the factors that impact treatment decisions in NSCLC. The presentation will be interactive featuring the use of iPads throughout the session. The following areas will be discussed:

  • Histologic and molecular testing; Value of retesting
  • Challenges and solutions to implementing different testing methods
  • Personalizing treatment based on molecular test results
  • Comparative safety and efficacy data of FDA approved treatment options
  • Emerging data
  • Acquired resistance
  • Addressing interchangeability of inhibitors
  • Risk assessment, genetic counseling and genetic testing for BRCA-related cancers
  • Clinical guidelines and current challenges in testing
  • Recent clinical trial updates on PARP inhibitors and platinum chemotherapy
  • Promising novel agents in clinical development

Q&A Session and Presentation Roundup

CME Information

AMA PRA Category 1 Credits™

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe Oncology. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

ANCC

Elsevier is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Elsevier is provider approved by the Florida Board of Nursing, Provider #50-4681, and the California Board of Registered Nursing, Provider #CEP 3257.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the EOCME, Elsevier’s accredited Provider Unit, and Rockpointe Oncology. Elsevier designates this activity for 1.0 CNE credits.

ACPE

Pharmacists – The Potomac Center for Medical Education is accredited by the Accreditation Council for Pharmacy education as a provider of continuing pharmacy education.

The Potomac Center for Medical Education designates this educational activity for a maximum of 1.0 hour (0.10 CEUs) of continuing education credit (UAN: xxx).

This is an application-based activity.

Faculty Information

Coming Soon